We use cookies for a better user experience. Read our Privacy Policy

I Agree

Cancer Immunotherapy Market

Cancer Immunotherapy Market (Therapy Type: Monoclonal Antibodies, Immune Checkpoint Inhibitors, PD-1/PD-L1, CTLA-4, Immune System Modulators, Cancer Vaccines, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Cancer Immunotherapy Market Outlook 2031

  • The global cancer immunotherapy market was valued over US$ 82.8 Bn in 2021
  • It is estimated to grow at a CAGR of 13.6% from 2022 to 2031
  • The global cancer immunotherapy market is expected to cross value of US$ 261.7 Bn by the end of 2031

Analysts’ Viewpoint on Global Cancer Immunotherapy Market Scenario

Novel innovations as a result of rise in the R&D activities are driving the cancer immunotherapy market. For instance, on June 6, 2022, a major clinical breakthrough was witnessed in the treatment of cancer with the development of a drug called dostarlimb, which is effective against the rectal cancer. Moreover, various companies are highly investing in the market, which creates a ‘big cheese’ for the cancer immunotherapy market. Hence, the popularity of cancer Immunotherapy treatment among the patients due to its cost friendliness and less side effects is one of the major reasons for the growth of the cancer immunotherapy market.

cancer immunotherapy market

Overview of Global Cancer Immunotherapy Market

Immunotherapy is a cancer treatment that improves the immune system's ability to fight cancer. It is a kind of biological treatment. Biological therapy makes use of compounds derived from biological creatures or lab-created copies of these substances.

Increase in R&D activities, improvements in efficacy & accuracy of newer medicines, surge in adoption of target therapy over standard therapy, and rise in prevalence of cancer are the major factors propelling the global cancer immunotherapy market. In addition, rise in incidence of cancer is a key factor driving the global cancer immunotherapy market. In the U.S., cancer is the biggest cause of mortality and disease, and it not only has a significant effect on the health of patients and survivors, but also has a major financial impact.

Several companies are increasingly investing in R&D activities to develop more effective treatments for cancer. For instance, TILT Bio therapeutics has announced over $10 million financing to the oncology immunotherapy assets. Companies such as Justin Wilson, partner & attorney at Withers & Rodgers, have discussed their opinion on innovations in the microbe in supporting the discovery of new drugs & treatments in the immunotherapy market.

Request a sample to get extensive insights into the Cancer Immunotherapy Market

Popularity of Cancer Immunotherapy Treatment among Patients Due to Cost-effectiveness and Less Side Effects

In terms of therapy type, the global cancer immunotherapy market has been classified into immune system modulators, immune checkpoint inhibitors, immune checkpoint inhibitors, and monoclonal antibodies. Monoclonal antibodies have been the treatment method of choice for a large segment of the global healthcare industry, giving it a significant advantage over other segments. Monoclonal antibodies have gained, as it is less expensive than other therapies. However, the global cancer immunotherapy market is expected to witness increase in demand for immune checkpoint inhibitors due to higher success rates and overall efficiency.

Based on therapeutic area, the global cancer immunotherapy market has been categorized into blood cancer, prostate cancer, melanoma, breast cancer, lung cancer, colorectal cancer, and other minor cancers. Breast cancer has been the most common target for immunotherapy. Increase in population of smokers and rise in total air pollution in metropolitan areas drive the lung cancer segment.

Rise in R&D Activities and High Efficacy of Newer Therapies to Augment Market

Rise in R&D activities in the field of cancer immunotherapy has led to the introduction of advanced variants with improved treatment efficacy and effectiveness. Immuno oncology has shown promising results in terms of increased survival and decreased toxicity. The market is likely to be propelled by a paradigm shift from traditional chemotherapies to immunotherapies. Immunotherapies in development are expected to offer more treatment options and better outcomes than currently available therapies. The introduction of newer drug classes, such as monoclonal antibodies and histone deacetylase (HDAC) inhibitors, aimed at multiple myeloma receptors, is projected to propel the global market. The market is likely to be driven by ongoing research on similar drugs with the goal of reducing side effects.

Monoclonal Antibodies to Remain Dominant Immunotherapeutic Drugs in Global Market

In terms of therapy type, the global cancer immunotherapy market has been classified into monoclonal antibodies, immune checkpoint inhibitors, PD-1/PD-L1, CTLA-4, immune system modulators, cancer vaccines, and others. The monoclonal antibody segment accounted for key market share in 2021. Monoclonal antibodies are the most commonly prescribed immunotherapeutic drugs in the world. Following Amgen's approval of Blincyto (blinatumomab), a bispecific antibody that targets B-cell lymphoblastic leukemia, monoclonal antibodies were developed as effective immunotherapeutic options.

Increase in research & development on the use of monoclonal bodies as naked antigen binding antibodies, conjugated antibodies, and bispecific antibodies has led to the discovery of new cancer therapeutic options.

High Cost of Cancer Immunotherapy Manufacturing R&D to Hamper Global Market Growth

The global cancer immunotherapy market is concerned about both research and manufacturing costs as well as market price for the end-user. For a developing organization, cancer immunotherapy research & development requires large amounts of resources, which raises worries about receiving finances. Research activities involving new technology development require significant investment, which is expected to be received with significant profits by the innovator. Cancer immunotherapy is a niche segment and requires high investment. This deters companies to enter the market due to uncertainty of receiving expected profit.

Regional Outlook of Global Cancer Immunotherapy Market

In terms of region, the global cancer immunotherapy market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is projected to be a highly lucrative market for cancer immunotherapy during the forecast period. Well-established healthcare infrastructure and increase in government initiatives are the major factors driving the market in the region. North America's large market share can be attributed to rise in number of patients suffering from cancer, increase in adoption rate of immunotherapy, and development of bioinformatics tools that enhance the drug development process.

The market in Asia Pacific is expected to experience the fastest growth during the forecast period. New and advanced immunotherapy drugs have been introduced in China and Japan. These countries have several ongoing clinical trials as well as FDA approvals for new drug molecules and combination therapies. Approval of new treatment drugs in China and Japan boosts the adoption of immunotherapy for treatment of tumors.

Analysis of Key Players in Global Cancer Immunotherapy Market

This report profiles major players in the global cancer immunotherapy market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The global cancer immunotherapy market is quite competitive, with the top players accounting for major share of the market and companies focusing on research & development to produce better pharmaceutical products for the existing diseases.

Leading players operating in the global cancer immunotherapy market are Amgen, Inc., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Sanofi, Janssen Biotech, Inc., Merck & Co., Inc., Pfizer, Inc., Spectrum Pharmaceuticals, Inc., Novartis AG, and Takeda Pharmaceuticals.

Request a custom report on Cancer Immunotherapy Market

Key Developments in Global Cancer Immunotherapy Market

Key players in the global cancer immunotherapy market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global cancer immunotherapy market. A few expansion strategies adopted by players operating in the global cancer immunotherapy market are:

  • In February 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM)
  • In April 2021, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer as well as esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

Global Cancer Immunotherapy Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 82.8 Bn

Market Forecast Value in 2028

US$ 261.7 Bn

Growth Rate (CAGR)

13.6%

Forecast Period

2022–2031

Historical Data Available for

2017-2020

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at global as well as regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.

Competition Landscape

  • Market share analysis by company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Therapy Type
    • Monoclonal Antibodies
    • Immune Checkpoint Inhibitors
    • PD-1/PD-L1
    • CTLA-4
    • Immune System Modulators
    • Cancer Vaccines
    • Others
  • Therapeutic Area
    • Lung Cancer
    • Colorectal Cancer
    • Breast Cancer
    • Prostate Cancer
    • Melanoma
    • Blood Cancers
    • Others
  • End-user
    • Hospitals
    • Ambulatory Surgical Centers (ASCs)
    • Cancer Research Centers
    • Clinics

Regions Covered

  • North America
  • Latin America
  • Europe
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • Amgen, Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Janssen Biotech, Inc.
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Spectrum Pharmaceuticals, Inc.
  • Novartis AG
  • Takeda Pharmaceuticals
  • Other Prominent players

Customization Scope

Available upon request

Pricing

Available upon request

Cancer Immunotherapy Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Frequently Asked Questions

How big was the global cancer immunotherapy market in 2021?

The global cancer immunotherapy market was valued over US$ 82.8 Bn in 2021

How big will be the cancer immunotherapy market in 2031?

The global cancer immunotherapy market is expected to surpass US$ 261.7 Bn by 2031

What is the CAGR of global cancer immunotherapy market during the forecast period (2022-2031)?

The global cancer immunotherapy market is anticipated to record CAGR of 13.6% from 2022 to 2031

What are the prominent trends impacting market growth?

Rise in R&D Activities, increase in effectivity & accuracy of newer therapies, and popularity of cancer immunotherapy treatment

Which region held key market share during the forecast period?

North America is expected to be a potential revenue generator for vendors during the forecast period

Who are the prominent players in the global cancer immunotherapy market?

Prominent players in the global cancer immunotherapy market include Amgen, Inc. Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Sanofi, Janssen Biotech, Inc., Merck & Co., Inc. Pfizer, Inc, Spectrum Pharmaceuticals, Inc., Novartis AG, and Takeda Pharmaceuticals.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Immunotherapy Market

4. Market Overview

    4.1. Introduction

        4.1.1. Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Cancer Immunotherapy Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Value Chain Analysis

    5.2. Pipeline Analysis

    5.3. Cancer Epidemiology

    5.4. COVID-19 impact

6. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapy Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Therapy Type, 2017–2031

        6.3.1. Monoclonal Antibodies

        6.3.2. Immune Checkpoint Inhibitors

        6.3.3. PD-1/PD-L1

        6.3.4. CTLA-4

        6.3.5. Immune System Modulators

        6.3.6. Cancer Vaccines

        6.3.7. Others

    6.4. Market Attractiveness Analysis, by Therapy Type

7. Global Cancer Immunotherapy Market Analysis and Forecast, by Therapeutic Area

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        7.3.1. Lung Cancer

        7.3.2. Colorectal Cancer

        7.3.3. Breast Cancer

        7.3.4. Prostate Cancer

        7.3.5. Melanoma

        7.3.6. Blood Cancer

        7.3.7. Others

    7.4. Market Attractiveness Analysis, by Therapeutic Area

8. Global Cancer Immunotherapy Market Analysis and Forecast, by End-user

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by End-user, 2017–2031

        8.3.1. Hospitals

        8.3.2. Ambulatory Surgical Centers (ASCs)

        8.3.3. Cancer Research Centers

        8.3.4. Clinics

    8.4. Market Attractiveness Analysis, by End-user

9. Global Cancer Immunotherapy Market Analysis and Forecast, by Region

    9.1. Key Findings

    9.2. Market Value Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Market Attractiveness Analysis, by Region

10. North America Cancer Immunotherapy Market Analysis and Forecast

    10.1. Introduction

        10.1.1. Key Findings

    10.2. Market Value Forecast, by Therapy Type, 2017–2031

        10.2.1. Monoclonal Antibodies

        10.2.2. Immune Checkpoint Inhibitors

        10.2.3. PD-1/PD-L1

        10.2.4. CTLA-4

        10.2.5. Immune System Modulators

        10.2.6. Cancer Vaccines

        10.2.7. Others

    10.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        10.3.1. Lung Cancer

        10.3.2. Colorectal Cancer

        10.3.3. Breast Cancer

        10.3.4. Prostate Cancer

        10.3.5. Melanoma

        10.3.6. Blood Cancer

        10.3.7. Others

    10.4. Market Value Forecast, by End-user, 2017–2031

        10.4.1. Hospitals

        10.4.2. Ambulatory Surgical Centers (ASCs)

        10.4.3. Cancer Research Centers

        10.4.4. Clinics

    10.5. Market Value Forecast, by Country, 2017–2031

        10.5.1. U.S.

        10.5.2. Canada

    10.6. Market Attractiveness Analysis

        10.6.1. By Therapy Type

        10.6.2. By Therapeutic Area

        10.6.3. By End-user

        10.6.4. By Country

11. Europe Cancer Immunotherapy Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Therapy Type, 2017–2031

        11.2.1. Monoclonal Antibodies

        11.2.2. Immune Checkpoint Inhibitors

        11.2.3. PD-1/PD-L1

        11.2.4. CTLA-4

        11.2.5. Immune System Modulators

        11.2.6. Cancer Vaccines

        11.2.7. Others

    11.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        11.3.1. Lung Cancer

        11.3.2. Colorectal Cancer

        11.3.3. Breast Cancer

        11.3.4. Prostate Cancer

        11.3.5. Melanoma

        11.3.6. Blood Cancer

        11.3.7. Others

    11.4. Market Value Forecast, by End-user, 2017–2031

        11.4.1. Hospitals

        11.4.2. Ambulatory Surgical Centers (ASCs)

        11.4.3. Cancer Research Centers

        11.4.4. Clinics

    11.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Italy

        11.5.5. Spain

        11.5.6. Rest of Europe

    11.6. Market Attractiveness Analysis

        11.6.1. By Therapy Type

        11.6.2. By Therapeutic Area

        11.6.3. By End-user

        11.6.4. By Country/Sub-region

12. Asia Pacific Cancer Immunotherapy Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Therapy Type, 2017–2031

        12.2.1. Monoclonal Antibodies

        12.2.2. Immune Checkpoint Inhibitors

        12.2.3. PD-1/PD-L1

        12.2.4. CTLA-4

        12.2.5. Immune System Modulators

        12.2.6. Cancer Vaccines

        12.2.7. Others

    12.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        12.3.1. Lung Cancer

        12.3.2. Colorectal Cancer

        12.3.3. Breast Cancer

        12.3.4. Prostate Cancer

        12.3.5. Melanoma

        12.3.6. Blood Cancer

        12.3.7. Others

    12.4. Market Value Forecast, by End-user, 2017–2031

        12.4.1. Hospitals

        12.4.2. Ambulatory Surgical Centers (ASCs)

        12.4.3. Cancer Research Centers

        12.4.4. Clinics

    12.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Market Attractiveness Analysis

        12.6.1. By Therapy Type

        12.6.2. By Therapeutic Area

        12.6.3. By End-user

        12.6.4. By Country/Sub-region

13. Latin America Cancer Immunotherapy Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Therapy Type, 2017–2031

        13.2.1. Monoclonal Antibodies

        13.2.2. Immune Checkpoint Inhibitors

        13.2.3. PD-1/PD-L1

        13.2.4. CTLA-4

        13.2.5. Immune System Modulators

        13.2.6. Cancer Vaccines

        13.2.7. Others

    13.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        13.3.1. Lung Cancer

        13.3.2. Colorectal Cancer

        13.3.3. Breast Cancer

        13.3.4. Prostate Cancer

        13.3.5. Melanoma

        13.3.6. Blood Cancer

        13.3.7. Others

    13.4. Market Value Forecast, by End-user, 2017–2031

        13.4.1. Hospitals

        13.4.2. Ambulatory Surgical Centers (ASCs)

        13.4.3. Cancer Research Centers

        13.4.4. Clinics

    13.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Market Attractiveness Analysis

        13.6.1. By Therapy Type

        13.6.2. By Therapeutic Area

        13.6.3. By End-user

        13.6.4. By Country/Sub-region

14. Middle East & Africa Cancer Immunotherapy Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Therapy Type, 2017–2031

        14.2.1. Monoclonal Antibodies

        14.2.2. Immune Checkpoint Inhibitors

        14.2.3. PD-1/PD-L1

        14.2.4. CTLA-4

        14.2.5. Immune System Modulators

        14.2.6. Cancer Vaccines

        14.2.7. Others

    14.3. Market Value Forecast, by Therapeutic Area, 2017–2031

        14.3.1. Lung Cancer

        14.3.2. Colorectal Cancer

        14.3.3. Breast Cancer

        14.3.4. Prostate Cancer

        14.3.5. Melanoma

        14.3.6. Blood Cancer

        14.3.7. Others

    14.4. Market Value Forecast, by End-user, 2017–2031

        14.4.1. Hospitals

        14.4.2. Ambulatory Surgical Centers (ASCs)

        14.4.3. Cancer Research Centers

        14.4.4. Clinics

    14.5. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.5.1. GCC Countries

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Market Attractiveness Analysis

        14.6.1. By Therapy Type

        14.6.2. By Therapeutic Area

        14.6.3. By End-user

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Player - Competition Matrix (by tier and size of companies)

    15.2. Market Share Analysis, by Company, 2021

    15.3. Company Profiles

        15.3.1. Amgen, Inc.

            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.1.2. Financial Analysis

            15.3.1.3. Growth Strategies

            15.3.1.4. SWOT Analysis

        15.3.2. F. Hoffmann-La Roche Ltd.

            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.2.2. Financial Analysis

            15.3.2.3. Growth Strategies

            15.3.2.4. SWOT Analysis

        15.3.3. Bristol-Myers Squibb Company

            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.3.2. Financial Analysis

            15.3.3.3. Growth Strategies

            15.3.3.4. SWOT Analysis

        15.3.4. Merck & Co., Inc.

            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.4.2. Financial Analysis

            15.3.4.3. Growth Strategies

            15.3.4.4. SWOT Analysis

        15.3.5. Spectrum Pharmaceuticals

            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.5.2. Financial Analysis

            15.3.5.3. Growth Strategies

            15.3.5.4. SWOT Analysis

        15.3.6. GlaxoSmithKline plc

            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.6.2. Financial Analysis

            15.3.6.3. Growth Strategies

            15.3.6.4. SWOT Analysis

        15.3.7. Pfizer, Inc.

            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.7.2. Financial Analysis

            15.3.7.3. Growth Strategies

            15.3.7.4. SWOT Analysis

        15.3.8. AstraZeneca plc

            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.8.2. Financial Analysis

            15.3.8.3. Growth Strategies

            15.3.8.4. SWOT Analysis

        15.3.9. Eli Lilly and Company.

            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.9.2. Financial Analysis

            15.3.9.3. Growth Strategies

            15.3.9.4. SWOT Analysis

        15.3.10. Takeda Pharmaceuticals

            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

            15.3.10.2. Financial Analysis

            15.3.10.3. Growth Strategies

            15.3.10.4. SWOT Analysis

List of Tables

Table 01: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 02: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

Table 03: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 04: Global Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Region, 2022 and 2031

Table 05: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country, 2022 and 2031

Table 06: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 07: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

Table 08: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 09: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

Table 10: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 11: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

Table 12: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 13: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

Table 14: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 15: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area, 2022 and 2031

Table 16: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 17: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

Table 18: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 19: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by therapeutic Area, 2022 and 2031

Table 20: Latin America Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user, 2022 and 2031

Table 21: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2022 and 2031

Table 22: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapy Type, 2022 and 2031

Table 23: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by Therapeutic Area 2022 and 2031

Table 24: Middle East & Africa Cancer Immunotherapy Market Value (US$ Mn) Forecast, by End-user 2022 and 2031

List of Figures

Figure 01: Global Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

Figure 02: Global Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

Figure 03: Global Cancer Immunotherapy Market Value Share Analysis, by End-user, 2022 and 2031

Figure 04: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type, 2022 and 2031

Figure 05: Global Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

Figure 06: Global Cancer Immunotherapy Market Attractiveness Analysis, by End-user, 2022 and 2031

Figure 07: North America Cancer Immunotherapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 08: North America Cancer Immunotherapy Market Value Share Analysis, by Country, 2022 and 2031

Figure 09: North America Cancer Immunotherapy Market Attractiveness Analysis, by Country, 2022 and 2031

Figure 10: North America Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

Figure 11: North America Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

Figure 12: North America Cancer Immunotherapy Market Value Share Analysis, by End-user, 2022 and 2031

Figure 13: Europe Cancer Immunotherapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 14: Europe Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 15: Europe Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

Figure 16: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

Figure 17: Europe Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

Figure 18: Europe Cancer Immunotherapy Market Attractiveness Analysis, by End-user, 2022 and 2031

Figure 1 9: Asia Pacific Cancer Immunotherapy Market Value (US$ Mn) Forecast, 2017–2028

Figure 20: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 21: Asia Pacific Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

Figure 22: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapy Type, 2022 and 2031

Figure 23: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by Therapeutic Area, 2022 and 2031

Figure 24: Asia Pacific Cancer Immunotherapy Market Value Share Analysis, by End-user, 2022 and 2031

Figure 25: Latin America Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 26: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

Figure 27: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type, 2022 and 2031

Figure 28: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

Figure 29: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

Figure 30: Latin America Cancer Immunotherapy Market Attractiveness Analysis, by End-user 2022 and 2031

Figure 31: Middle East & Africa Cancer Immunotherapy Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 32: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by Country/Sub-region, 2022 and 2031

Figure 33: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by Therapy Type, 2022 and 2031

Figure 34: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by Therapeutic Area, 2022 and 2031

Figure 35: Middle East & Africa Cancer Immunotherapy Market Attractiveness Analysis, by End-user, 2022 and 2031

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

104

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved